key: cord-0922335-ilgfkk87
authors: Kalemci, Serdar; Sarıhan, Aydın; Zeybek, Arife
title: Does asthma affect outcomes of patients with COVID-19 infections?
date: 2020-09-28
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2020.09.019
sha: da7bfdf1838078dbda95992f289a73f5f882572b
doc_id: 922335
cord_uid: ilgfkk87

nan

We have read the article recently published by Mahdavinia et al. entitled "Asthma prolongs intubation in COVID-19 with great interest" (1) .

This article has shown that asthma was independently associated with prolonged ventilation time in COVID-19 patients. In addition, asthma was associated with obesity, which the authors point out "is another predictor of poor outcome in COVID-19 patients".

Allergic diseases, asthma and COPD were not found to be risk factors in a study conducted on 140 patients with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) in China. Asthma is a heterogeneous disease characterized by Type 2 eosinophilic inflammation in more than 50% patients. Eosinophil count is decreased in the peripheral blood of patients infected with SARS-CoV-2. The increased eosinophil count in the airways of asthma patients has been considered as a potential protective mechanism against the exaggerated inflammatory responses of severe COVID-19 phenotype. (2, 3) It is known that the level of angiotensin-converting enzyme 2 (ACE-2) in the lung tissues of COVID-19 patients increases and is found to play an important role in the pulmonary involvement(4). It is proposed that inhaled corticosteroids, as the essential component of asthma treatment, may have a positive impact on the prognosis of COVID-19 patients by reducing the level of ACE-2 in lung tissues (5) .

We conclude that regularity and dosage of inhaled corticosteroid administration as reported in the medical history of asthma patients may have an impact on the treatment outcomes. Although the analyses in the study of Mahdavinia, et al (1) adjusted for albuterol and systemic steroids use, it would be important to know how many of the patients were being treated with inhaled corticosteroids and the outcomes in those patients. Moreover, although the authors state that "peripheral eosinophilia was assocaited with asthma" in their study, more information regarding the type of inflammation in the asthma patients involved in this study would be enlightening with respect to asthma heterogeneity and COVID-19 outcomes. .

Asthma prolongs intubation in COVID-19

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Is asthma protective against COVID-19?

Pathogenesis of COVID-19 from a cell biology perspective

COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?